Preventing HIV in newborns to achieve long-term remission without treatment
Official title: Early prevention interventions towards ART-free pediatric HIV remission
Funded at Tulane University of Louisiana · NIH-11012325 · Data updated 2026-11-12
This study is looking at how giving certain HIV medications to newborns right after birth can help prevent the virus from spreading from mother to child and keep the babies healthy without needing ongoing treatment, so we can find the best timing and combination of drugs for the little ones at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | February 16, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $642,228 |
| NIH project number | 5R01MH133474-03 |
| Project ID | NIH-11012325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are newborns at high risk of HIV transmission from their mothers.
✕Less likely to help
Patients who are older than infants or those who are not at risk of HIV transmission will not benefit from this research.
What this research studies
This research focuses on developing early intervention strategies to prevent HIV transmission from mother to child and to achieve sustained remission in infants without the need for ongoing antiretroviral therapy. The approach involves administering a specific combination of antiretroviral drugs shortly after birth to rapidly suppress the virus. The study aims to determine the optimal timing and regimen for treatment in neonates, as preliminary findings suggest that early intervention can lead to long-lasting viral suppression. By understanding how age and timing affect treatment outcomes, the research seeks to improve the health of vulnerable infants at risk of HIV.
Why it matters
Potential benefit: If successful, this research could lead to a breakthrough in HIV treatment for infants, allowing them to live without the need for lifelong antiretroviral therapy.
How similar studies have gone: Other research has shown promising results with early antiretroviral interventions in infants, indicating potential for success in this approach.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Xu, Huanbin — Tulane University of Louisiana
- Study coordinator: Xu, Huanbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.